-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Benzinga·08/11/2026 14:19:33
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.